##  [Home](/us-en/home "Home") 

  ![Q2 2026 results](/us-en/sites/novartis_us/files/styles/cta_image/public/2026-07/q2-2026-thumbnail.jpg?h=5b3035e0&itok=Ll-on8WX "Q2 2026 results") 

 

##  Novartis Financial Results – Q2 2026 

Novartis announces the company’s financial results for the second quarter and first half of 2026.



 

 [Learn more about the Q2 2026 results](https://www.novartis.com/events/novartis-financial-results-q2-2026 "Learn more about the Q2 2026 results") 



 

 



 





 ![Two employees in hard hats talking in a manufacturing facility ](/us-en/sites/novartis_us/files/styles/cta_image/public/2026-03/BJORN_NOVARTIS_RLT%20-%20Main%20Sequence%20RePurpose%202%20271025%20AM%20V1.00_00_31_14.Still015%20%281%29.jpg?h=8f74817f&itok=gR3Yz9R2 "Two employees in hard hats talking in a manufacturing facility ") 

 

##  Novartis breaks ground on new RLT manufacturing site in Denton, Texas 

Novartis' first Texas-based manufacturing facility expands US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide.



 

 [Learn more](https://www.novartis.com/us-en/news/media-releases/novartis-breaks-ground-denton-texas-radioligand-therapy-site-construction-now-underway-across-all-new-us-facilities "Learn more") 



 

 



 





 [ 

 ![Scientist in lab](/us-en/sites/novartis_us/files/styles/cards_1_3/public/2023-07/boh-landing-hero.jpg?itok=HorfYX7O "Scientist in lab") 

 

###  Discover our medicines 

See how our innovative medicines are addressing society's greatest health challenges. 

 

 

 ](/us-en/about/therapeutic-areas) [ 

 ![Doctor and patient talking in hallway](/us-en/sites/novartis_us/files/styles/cards_1_3/public/2024-01/doctor-patient-talking-hallway-2807-115dpi-RGB.jpg?itok=chPvarYQ "Doctor and patient talking in hallway") 

 

###  Commitment to patients 

From research and development to expanding access, uncover our commitment to improving people's lives. 

 

 

 ](/us-en/patients-and-caregivers) [ 

 ![business people meeting around a table image_0](/us-en/sites/novartis_us/files/styles/cards_1_3/public/2022-03/business-people-meeting-around-a-table-image_0.jpg?itok=9f5nNejj "business people meeting around a table image_0") 

 

###  Inspired by purpose 

Learn about our people and culture, and how we're driven by our mission to reimagine medicine.

 

 

 ](https://www.novartis.com/about/people-and-culture) 





 

 

 



##  Latest News 

 [Oct 07, 2026

- Media Release

 

###  Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

 ](/us-en/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu) [Oct 07, 2026

- Media Release

 

###  Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026

 ](/us-en/news/media-releases/novartis-advances-multiple-sclerosis-innovation-late-breaking-remibrutinib-and-broad-portfolio-data-mstoronto2026) [Sep 08, 2026

- Media Release

 

###  Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) 

 ](/us-en/news/media-releases/novartis-provides-update-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-treatment-myotonic-dystrophy-type-1-dm1) 





 

 [Read all news ](/us-en/news/news-archive?type=media_release "Read all news ") 

 





    ![Scientist with microscope](/us-en/sites/novartis_us/files/styles/cosmos_banner_half_image_large/public/2025-04/scientist-with-microscope_0.jpg?h=3a5caf61&itok=LHI0mt1B "Scientist with microscope ") 

 

 

 

##  Welcome to where we thrive 

Discover how you can join us in our mission to change people's lives. 

 [Join us ](https://www.novartis.com/us-en/careers "Join us ") 

 

 

 



 

 

 

 



##  Resource links 

 

 

 [About Novartis ](/us-en/about/novartis-us "About Novartis ") 



 [Commitment to patients and caregivers ](/us-en/patients-and-caregivers/novartis-commitment-patients-and-caregivers "Commitment to patients and caregivers ") 



 [Healthcare professional resources ](/us-en/healthcare-professionals "Healthcare professional resources ") 



 [Products ](https://www.novartis.com/us-en/about/products "Products ") 



 [Pipeline ](https://www.novartis.com/research-development/novartis-pipeline "Pipeline ") 



 [Contact us](/us-en/about/contact-us "Contact us")